J&J to discontinue HIV vaccine trial

(Reuters) -Johnson & Johnson said on Wednesday the company and its partners will discontinue the late-stage trial of an HIV vaccine after it was found ineffective at preventing infections.

The global trial began in 2019 and was carried out at more than 50 sites. However, there were no safety concerns with the vaccine regimen. This is yet another setback in the quest for a HIV vaccine.

Another HIV vaccine by J&J also failed a mid-stage study in a population of young women in sub-Saharan Africa in 2021.

(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)